14 Biotechnology Stocks to Sell Now

This week, 14 Biotechnology stocks are worse, according to the Portfolio Graderdatabase. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Biogen Inc. (BIIB) gets weaker ratings this week as last week’s C drops to a D. Biogen Inc. is a global biotechnology company that meets the needs of therapeutic care providers and recipients. For more information, get Portfolio Grader’s complete analysis of BIIB stock.

This week, Bellicum Pharmaceuticals Inc’s (BLCM) rating worsens to a D from the company’s C rating a week ago. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of BLCM stock.

Versartis, Inc. (VSAR) slips from a C to a D this week. The company also gets F’s in earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of VSAR stock.

This is a rough week for Achillion Pharmaceuticals, Inc. (ACHN). The company’s rating falls to D from the previous week’s C. Achillion Pharmaceuticals, Inc. focuses on the discovery, development and commercialization of innovative treatments for infectious diseases. The company also gets F’s in earnings revisions and return on equity. For more information, get Portfolio Grader’s complete analysis of ACHN stock.

Dicerna Pharmaceuticals, Inc.’s (DRNA) rating weakens this week, dropping to a F versus last week’s D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of DRNA stock.

Slipping from a C to a D rating, Raptor Pharmaceutical Corp. (RPTP) takes a hit this week. Raptor Pharmaceutical Corp. researches existing drugs to improve them through specialized drug targeting methods and formulation changes. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of RPTP stock.

Aeterna Zentaris Inc. (AEZS) is having a tough week. The company’s rating falls from a C to a D. Aeterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology with expertise in drug discovery, development and commercialization. The company also gets F’s in earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of AEZS stock.

This week, Agenus Inc. (AGEN) drops from a C to a D rating. Agenus Inc. is a biotechnology company that engages in developing and commercializing technologies to treat cancers and infectious diseases. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of AGEN stock.

Array BioPharma Inc. (ARRY) earns a F this week, moving down from last week’s grade of D. Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. The company also gets F’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of ARRY stock.

Tonix Pharmaceuticals Holding Corp. (TNXP) declines this week from a C to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of TNXP stock.

Cancer Genetics, Inc. (CGIX) experiences a ratings drop this week, going from last week’s C to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of CGIX stock.

BioTime, Inc. (BTX) earns a D this week, moving down from last week’s grade of C. BioTime, Inc. is a biotechnology company that focuses on regenerative medicine and blood plasma volume expanders. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of BTX stock.

Aurinia Pharmaceuticals Inc. (AUPH) slips from a C to a D this week. The company also gets F’s in sales growth, earnings growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of AUPH stock.

Pieris Pharmaceuticals, Inc. (PIRS) is having a tough week. The company’s rating falls from a C to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of PIRS stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/02/14-biotechnology-stocks-to-sell-now-2/.

©2021 InvestorPlace Media, LLC